2018
Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories
Mossanen M, Wang Y, Szymaniak J, Tan W, Huynh M, Preston M, Trinh Q, Sonpavde G, Kibel A, Chang S. Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World Journal Of Urology 2018, 37: 2059-2065. PMID: 30446799, DOI: 10.1007/s00345-018-2550-x.Peer-Reviewed Original ResearchConceptsBladder cancerProgression to muscle-invasive diseaseNon-muscle-invasive bladder cancerHigh-risk disease patientsEORTC risk calculatorHigh-risk NMIBCManagement of NMIBCMuscle-invasive diseaseLow-risk tumorsBiologically heterogeneous diseaseHigh-risk diseaseSurveillance of patientsMethodsA Markov modelLong-term surveillanceHigh-risk groupPatient risk groupsOverall cost of careCost of surveillanceCost of careIntermediate-riskSurveillance cystoscopyExpensive malignanciesIndex patientPatient basisNMIBCIntravesical device-assisted therapies for non-muscle-invasive bladder cancer
Tan W, Kelly J. Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nature Reviews Urology 2018, 15: 667-685. PMID: 30254383, DOI: 10.1038/s41585-018-0092-z.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerElectromotive drug administrationDevice-assisted therapiesBladder cancerHyperthermic chemotherapyDevice-assisted treatmentsIntravesical adjuvant treatmentHigh-risk diseaseResults of randomized trialsRisk of recurrenceRisk of progressionAlternative to BCGEffective treatment optionSingle-arm study designBladder cancer diagnosisBCG failureRandomized controlled trialsMaintenance regimensAdjuvant treatmentPatient cohortTreatment optionsRandomized trialsDrug AdministrationControlled trialsClinical guidelinesDoes urinary cytology have a role in haematuria investigations?
Tan W, Sarpong R, Khetrapal P, Rodney S, Mostafid H, Cresswell J, Watson D, Rane A, Hicks J, Hellawell G, Davies M, Srirangam S, Dawson L, Payne D, Williams N, Brew‐Graves C, Feber A, Kelly J, Sridhar A, Lamb B, Ocampo F, McBain H, Baillie K, Middleton K, Knight H, Maher S, Pathmanathan B, Harmathova A, Pelluri S, Pati J, Cossons A, Scott C, Madaan S, Bradfield S, Wakeford N, Dann, Cook J, Cornwell M, Mills R, Thomas, Reyner S, Vallejera G, Adeniran P, Masood S, Whotton N, Dent K, Pearson S, Hatton J, Newton M, Hheeney E, Green K, Evans S, Rogers M, Gupwell K, ley S, Brown A, McGrath J, Lunt N, Hill P, inclair A, Paredes‐Guerra A, Holbrook B, Ong E, Wardle H, Wilson D, Bayles A, Fennelly R, Tribbeck M, Ames K, Taylor J, Edmunds E, Moore J, Mckinley S, Nolan T, peed A, Tunnicliff A, Fossey G, Williams A, George M, Hutchins I, Einosas R, Richards A, Henderson A, Appleby B, Kehoe L, Gladwell L, Drakeley S, Davies J, Krishnan R, Roberts H, Main C, Jain S, Dumville J, Wilkinson N, Taylor J, Thomas F, Goulden K, Vinod C, Green E, Waymont C, Rogers J, Grant A, Carter V, Heap H, Lomas C, Cooke P, Scarratt L, Hodgkiss T, Johnstone D, Johnson J, Allsop J, Rothwell J, Connolly K, Cherian J, Ridgway S, Coulding M, Savill H, Mccormick J, Clark M, Collins G, Jewers K, Keith S, Bowen G, Hargreaves J, Riley K, Rees A, Williams S, Dukes S, Goffe A, Mistry R, Chadwick J, Cocks S, Hull R, oftus A, Baird Y, Moore S, Greenslade S, Margalef J, Chadbourn I, Harris M, Clitheroe P, Connolly S, Hodgkinson S, Haydock H, Storr E, Cogley L, Natale S, Lovegrove W, Slack K, Nash D, Smith K, Walsh J, Guerdette A, Hill M, Taylor B, Sinclair E, Perry M, Debbarma M, Hewitt D, Sriram R, Power A, Cannon J, Devereaux L, Thompson A, Atkinson K, Royle L, Madine J, MacLean K. Does urinary cytology have a role in haematuria investigations? BJU International 2018, 123: 74-81. PMID: 30003675, PMCID: PMC6334509, DOI: 10.1111/bju.14459.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Transitional CellFalse Negative ReactionsFalse Positive ReactionsFemaleHematuriaHumansKidney NeoplasmsMaleMiddle AgedNeoplasm GradingNeoplasm StagingPredictive Value of TestsProspective StudiesTomography, X-Ray ComputedUltrasonographyUreteral NeoplasmsUrinary Bladder NeoplasmsUrineUrographyConceptsUpper tract urothelial cancerPositive urine cytologyAccuracy of urinary cytologyDiagnosis of bladder cancerUrine cytologyHigh-risk cancerNegative predictive valuePositive predictive valueBladder cancerHaematuria investigationsUrinary cytologyInvasive testingDiagnostic accuracy of urinary cytologyMuscle-invasive bladder cancerProspective observational study of patientsMulticentre prospective observational studyObservational study of patientsPredictive valueEndoscopic tumor resectionPositive cytology resultsUpper tract imagingHigh-risk diseaseOutcomes of patientsDiagnosed bladder cancerStudy of patients
2015
Is Prebiopsy MRI Good Enough to Avoid Prostate Biopsy? A Cohort Study Over a 1-Year Period
Lamb B, Tan W, Rehman A, Nessa A, Cohen D, O'Neil J, Green J, Hines J. Is Prebiopsy MRI Good Enough to Avoid Prostate Biopsy? A Cohort Study Over a 1-Year Period. Clinical Genitourinary Cancer 2015, 13: 512-517. PMID: 26231912, DOI: 10.1016/j.clgc.2015.06.007.Peer-Reviewed Original ResearchConceptsMultiparametric magnetic resonance imagingPrebiopsy multiparametric magnetic resonance imagingNational Comprehensive Cancer NetworkProstate multiparametric magnetic resonance imagingTransrectal ultrasound prostate biopsySignificant prostate cancerTransrectal ultrasound biopsyProstate biopsyTransrectal ultrasoundProstate cancerNational Comprehensive Cancer Network high-riskSensitivity of multiparametric magnetic resonance imagingDetect clinically significant prostate cancerSystematic 12-core prostate biopsyClinically significant prostate cancerMRI scansPredictive valueNegative MRI scansGleason score 8High-risk diseasePositive MRI scansNegative predictive valuePositive predictive valueComprehensive Cancer NetworkRisk of complications